Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.1 Letolizumab does not induce platelet activation in vitro and does not affect coagulation factors or platelet counts/function after repeated dosing in non-human primates.
Purity:
98.80%
CAS Number:
[1450981-87-9]
Target:
TNF|||Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
